Search
Bortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigational[A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and … [L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995.
Synonyms: N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamideProducts: BORTEZOMIB EGCeftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigational[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of … [A232920] β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately
Products: CEFTAZIDIMA EGGlucosamine
go.drugbank.com/drugs/DB01296ApprovedOsteoarthritis (OA) is a progressive and degenerative joint disease marked by loss of cartilage, bone changes, and synovial membrane inflammation. Treatment with chondroprotective drugs, such as glucosamine sulfate may offer additional b...
Mixtures: flexijoint 3-in-1 Joint Care Powder, OSTEOACTIV 3-in-1 Joint Formula PowderProducts: GLUCOSAMINA SOLFATO EG, GLUCOSAMINA E-PHARMA TRENTOTadalafil
go.drugbank.com/drugs/DB00820ApprovedInvestigational[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. … Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.
Categories: Drugs Used in Erectile Dysfunction, Drugs Used in Benign Prostatic HypertrophyProducts: TADALAFIL EG, TADALAFIL EG STADAEsomeprazole
go.drugbank.com/drugs/DB00736ApprovedInvestigationalEsomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme … increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.
International brands: ES-ODProducts: E-SOME, ESOMEPRAZOLO EGKetorolac
go.drugbank.com/drugs/DB00465ApprovedInvestigationalKetorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution.
Products: KETOROLAC EGLevocetirizine
go.drugbank.com/drugs/DB06282ApprovedInvestigational[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Products: LEVOCETIRIZINA EGApixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban was approved by the FDA on December 28, 2012[L6043]. … Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic
Products: APIXABAN EGValsartan
go.drugbank.com/drugs/DB00177ApprovedInvestigational[A174124,A173869] Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States. … [A174157,A174160,A174163] Improvements in chronic kidney disease with valsartan include both clinically and statistically significant decreases in urinary albumin and protein excretion in patients diagnosed
Mixtures: VALSACOR COMP 160/25MG, VALSACOR COMP 160/25MGCategories: Agents Acting on the Renin-Angiotensin SystemCephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approved[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.[L6547]
Synonyms: (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidProducts: LUPICEFF ER, CEFALON ® ER